BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 19453817)

  • 21. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana.
    Nacher M; Carme B; Sainte Marie D; Couppié P; Clyti E; Guibert P; Pradinaud R
    Ann Trop Med Parasitol; 2001 Jun; 95(4):331-6. PubMed ID: 11454242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
    Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
    J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical features and diagnosis of mucocutaneous leishmaniasis in patients of an endemic area in Salta].
    Sosa Estani S; Campanini A; Sinagra A; Luna C; Peralta M; Coutada V; Medina L; Riarte A; Salomón D; Gómez A; Segura EL
    Medicina (B Aires); 1998; 58(6):685-91. PubMed ID: 10347960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine.
    Botelho AC; Mayrink W; Oliveira RC
    Acta Trop; 2009 Nov; 112(2):143-8. PubMed ID: 19631187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?
    Gomes-Silva A; de Cássia Bittar R; Dos Santos Nogueira R; Amato VS; da Silva Mattos M; Oliveira-Neto MP; Coutinho SG; Da-Cruz AM
    Clin Exp Immunol; 2007 Sep; 149(3):440-4. PubMed ID: 17614975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mucocutaneous leishmaniasis in Morocco, evidence of the parasite's ecological evolution?].
    Iguermia S; Harmouche T; Mikou O; Amarti A; Mernissi FZ
    Med Mal Infect; 2011 Jan; 41(1):47-8. PubMed ID: 20947275
    [No Abstract]   [Full Text] [Related]  

  • 27. Cutaneous leishmaniasis: successful treatment with itraconazole.
    Consigli J; Danielo C; Gallerano V; Papa M; Guidi A
    Int J Dermatol; 2006 Jan; 45(1):46-9. PubMed ID: 16426375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A patient with long-term, unrecognized leishmaniasis].
    Rabelink NM; de Steenwinkel JE; van Biezen P; van Daele PL; Gyssens IC
    Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2715-9. PubMed ID: 17194010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymerase chain reaction (PCR) is highly sensitive for diagnosis of mucosal leishmaniasis.
    Oliveira JG; Novais FO; de Oliveira CI; da Cruz Junior AC; Campos LF; da Rocha AV; Boaventura V; Noronha A; Costa JM; Barral A
    Acta Trop; 2005 Apr; 94(1):55-9. PubMed ID: 15777720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil.
    Turetz ML; Machado PR; Ko AI; Alves F; Bittencourt A; Almeida RP; Mobashery N; Johnson WD; Carvalho EM
    J Infect Dis; 2002 Dec; 186(12):1829-34. PubMed ID: 12447770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
    Esfandiarpour I; Dabiri SH
    Int J Dermatol; 2007 Aug; 46(8):848-52. PubMed ID: 17651170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MMP-9 activity is induced by Leishmania braziliensis infection and correlates with mucosal leishmaniasis.
    Maretti-Mira AC; de Pinho Rodrigues KM; de Oliveira-Neto MP; Pirmez C; Craft N
    Acta Trop; 2011 Aug; 119(2-3):160-4. PubMed ID: 21663729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate.
    Basile G; Cristofaro G; Locatello LG; Vellere I; Piccica M; Bresci S; Maggiore G; Gallo O; Novelli A; Di Muccio T; Gramiccia M; Gradoni L; Gaiera G; Bartoloni A; Zammarchi L
    Int J Infect Dis; 2020 Aug; 97():204-207. PubMed ID: 32505874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leishmaniasis in patients with chronic renal failure: a diagnostic and therapeutic challenge for the clinician.
    Maggi P; Gaudiano V; Valente M; Latorraca A; Cavaliere RL; Marroni M; Larocca AM; Stagni G; Lopez T; Pastore G
    J Nephrol; 2004; 17(2):296-301. PubMed ID: 15293532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humoral immune responses among mucosal and cutaneous leishmaniasis patients caused by Leishmania braziliensis.
    Valli LC; Passos VM; Dietze R; Callahan HL; Berman JD; Grogl M
    J Parasitol; 1999 Dec; 85(6):1076-83. PubMed ID: 10647040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment.
    Passos VM; Barreto SM; Romanha AJ; Krettli AU; Volpini AC; Lima e Costa MF
    Bull World Health Organ; 2000; 78(8):968-74. PubMed ID: 10994280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for mucosal manifestation of American cutaneous leishmaniasis.
    Machado-Coelho GL; Caiaffa WT; Genaro O; Magalhães PA; Mayrink W
    Trans R Soc Trop Med Hyg; 2005 Jan; 99(1):55-61. PubMed ID: 15550262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse.
    Bourreau E; Ginouves M; Prévot G; Hartley MA; Gangneux JP; Robert-Gangneux F; Dufour J; Sainte-Marie D; Bertolotti A; Pratlong F; Martin R; Schütz F; Couppié P; Fasel N; Ronet C
    J Infect Dis; 2016 Jan; 213(1):105-11. PubMed ID: 26123564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imported mucosal leishmaniasis in a traveler.
    Scope A; Trau H; Bakon M; Yarom N; Nasereddin A; Schwartz E
    Clin Infect Dis; 2003 Sep; 37(6):e83-7. PubMed ID: 12955668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mucocutaneous leishmaniasis in Panama. Etiologic agent, epidemiologic and clinical aspects].
    Sáenz RE; Paz HM; de Rodriguez GC; de Vásquez AM; Mata RE; Johnson CM
    Rev Med Panama; 1989 Jan; 14(1):6-15. PubMed ID: 2727332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.